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RESEARCH ARTICLE
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Abstract
Schistosomiasis control and elimination has priority in public health agendas in several sub-
Saharan countries. However, achieving these goals remains a substantial challenge. In
order to assess progress of interventions and treatment efficacy it is pertinent to have accu-
rate, feasible and affordable diagnostic tools. Detection of Schistosoma mansoni infection
by circulating cathodic antigen (CCA) in urine is an attractive option as this measure
describes live worm infection noninvasively. In order to interpret treatment efficacy and re-
infection levels, knowledge about clearance of this antigen is necessary. The current study
aims to investigate, whether antigen clearance as a proxy for decreasing worm numbers is
reflected in decreasing CCA levels in urine shortly after praziquantel treatment. Here CCA
levels are measured 24 hours post treatment in response to both a single and two treat-
ments. The study was designed as a series of cross-sectional urine and stool sample collec-
tions from 446 individuals nested in a two-arm randomised single blinded longitudinal
clinical trial cohort matched by gender and age (ClinicalTrials.gov Identifier: NCT00215267)
receiving one or two praziquantel treatments. CCA levels in urine were determined by car-
bon-conjugated monoclonal antibody lateral flow strip assay and eggs per gram faeces for
S. mansoni and soil-transmitted helminths by Kato-Katz. Significant correlations between
CCA levels and S. mansoni egg count at every measured time point were found and con-
firmed the added beneficial effect of a second treatment at two weeks after baseline. Fur-
thermore, presence of hookworm was found not to be a confounder for CCA test specificity.
Twenty-four hours post treatment measures of mean CCA scores showed significant reduc-
tions. In conclusion, removal of CCA in response to treatment is detectable as a decline in
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CCA in urine already after 24 hours. This has relevance for use and interpretation of labora-
tory based and point-of-care CCA tests in terms of treatment efficacy and re-infection pro-
portions as this measure provides information on the presence of all actively feeding stages
of S. mansoni, which conventional faecal microscopy methods do not accurately reflect.
Trial registration
ClinicalTrials.gov NCT00215267
Author summary
Large scale efforts to control schistosomiasis in several sub-Saharan countries are in prog-
ress. In order to accurately monitor the effect of interventions, we need diagnostic tools
which are highly specific, sensitive, affordable and easy to use and implement. For Schisto-
soma mansoni detection the circulating cathodic antigen (CCA) is an attractive option as
this antigen is a measure of actively feeding worms and can be measured in urine samples.
However, knowledge about how fast this antigen is cleared in response to treatment with
praziquantel is necessary for interpretation of consecutive measures based on CCA in
order to use this tool optimally. Here we show that CCA is already significantly reduced
24 hours after treatment both in single and double treatment regimens in a community
sample from Musoli Village, Uganda. Furthermore, the data supports interpretation of
trace measures of CCA as positive since the majority of individuals with trace measures
respond to treatment. These observations provide a basis for extended use of CCA-based
tools in monitoring treatment efficacy and possibilities for logistically advantageous prev-
alence screening strategies.
Introduction
The ambitious London declaration prompted by the WHO 2012 roadmap to combat neglected
tropical diseases commits to global schistosomiasis control by 2020 [1, 2]. Mass drug adminis-
tration with praziquantel is the most widely implemented intervention for control. However,
the necessity of an inter-disciplinary approach incorporating other strategies, such as commu-
nity health education, improved safe water supply, sanitation and control of intermediate hosts,
has become evident for targeting elimination of this poverty associated disease [3]. For elimina-
tion strategies, where low infection intensities and focal epidemiology must be addressed in the
later stages of a control programme, a test-then-treat approach based on point-of-care tests,
preferably incorporated in integrated disease control programmes, becomes relevant in contrast
to continuous reliance on mass drug administration only protocols.
In order to accurately monitor the progress of interventions aiming at reducing, controlling
or even regionally eliminating transmission, we need highly specific, sensitive, feasible and
affordable diagnostic tools, which optimally live up to all the ASSURED criteria (Affordable,
Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable to end-
users) [4, 5]. Schistosoma spp. worm antigens, which are released by living worms, are attrac-
tive targets compared to specific antibodies as they enable identification of currently infected
individuals compared to individuals with previous infection. This is very relevant for assessing
treatment efficacy as praziquantel kills adult schistosomes and mature eggs, but does not affect
the immature worm and egg stages [6–8].
Schistosoma mansoni CCA clearance in response to treatment
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Circulating cathodic antigen (CCA), which is a mucin-type glycoprotein antigen [9], regur-
gitated by Schistosoma spp. [10–14], has been shown to be a good measure for active Schisto-
soma mansoni infection [15]. CCA is excreted into the bloodstream as soon as schistosomules
start actively feeding and at least in high dose mouse models the antigen level is positively cor-
related to worm burden [16]. In humans the earliest verifiable detection point so far demon-
strated is four weeks post infection [17]. In addition, CCA can be detected in sera and breast
milk from infected individuals [18]. CCA detectable in human urine was first described by
Carlier et al. (1975) and Deelder et al. (1976) [11, 19]. However, the potential of this antigen
was not recognised until recently [20].
Two robust immunochromatographic methods for direct CCA detection in human urine
are now published; a laboratory based strip test (using colloidal carbon labelling) and a com-
mercially available point-of-care test (POC-CCA, Rapid Medical Diagnostics). Rapid antigen
clearance after praziquantel treatment is essential for CCA-based diagnostic tools to be used
for interpreting treatment efficacy, re-infection dynamics and potential development of drug
resistance. Furthermore, knowledge of antigen clearance is very relevant for identifying target
groups harbouring persistent active infection such as egg negative individuals. In this study
the laboratory based lateral flow urine strip test was used to investigate whether changes in
CCA score were detectable as early as 24 hours after treatment in urine samples from a com-
munity living in a S. mansoni high endemic area by Lake Victoria, Uganda. Furthermore, the
relationship between S. mansoni egg output and CCA score in relation to age groups and
responses to a single versus double treatment schedules were assessed.
Materials and methods
Study design
The current study is based on a series of cross-sectional sampling points nested in a two-arm
cohort randomised single blinded longitudinal clinical trial on “The effect of praziquantel
treatment on Schistosoma mansoni morbidity and re-infection along Lake Victoria, Uganda”
(ClinicalTrials.gov Identifier: NCT00215267). A questionnaire based census formed the basis
for random recruitment of participants above seven years of age stratified by gender and age
[21, 22]. Sample size for the clinical trial set-up was estimated to 552 individuals using cure
rate data from Lake Albert, Uganda [23] with a power of 90%, significance level of α = 0,05
and an anticipated drop-out from baseline (2005) to finalisation (2007) of 40%. Randomisation
to either the arm receiving one dose of praziquantel treatment (1 Tx) or the arm receiving a
second dose two weeks (2 Tx) after baseline was done by a scientist not involved in treatment
and laboratory work using computer generated random numbers [24]. The study was blinded
for examiners, but participants were fully informed of treatment regimen. Urine samples were
investigated at five time points and stool samples at two time points after baseline (Fig 1). Sam-
ple sizes for each analysis are stated; no-show or difficulty delivering stool/urine for individuals
at some time points account for missing data (S1 Dataset).
Study area and population
Study participants were recruited from Musoli Village, Mayuge District in south-east Uganda,
which is located along Lake Victoria. Mayuge District is located 1161m above sea level and
receives annual precipitation ranging from 600-1100mm with average temperatures from 19–
27˚C [25]. This area of Lake Victoria displays high perennial S. mansoni transmission and no
S. haematobium transmission (personal communication N. Kabatereine). The only water
source available to Musoli Village for both domestic and recreational use was Lake Victoria,
hence exposing the population to schistosomiasis. Albeit, that Mayuge District authority had
Schistosoma mansoni CCA clearance in response to treatment
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implemented praziquantel mass drug administration for control purposes, Musoli Village had
not yet received treatment at the time of the study. Besides fishing, the local economy relies on
subsistence farming.
Ethical considerations
Ethical approval was obtained from the Higher Degrees Research and Ethics Committee of the
School of Public Health, Makerere University. Ethical clearance was granted by the Uganda
National Council of Science and Technology (Reference number: UNCST:HS59).
Informed consent written in Lusoga, which is the most commonly used local language, was
obtained from each adult participant. Assent was obtained from participants under 15 years of
age, which also were required to present a signature from a parent or guardian. Participants were
free to withdraw from the study at any point in time without facing any form of repercussion.
All participants were treated with standard 40mg/kg single dose praziquantel (Distocide
600mg, Shin Poong Pharmaceuticals) at baseline irrespective of infection status. Furthermore,
400mg of albendazole (Alzental 400mg, Shin Poong Pharmaceuticals) was given to each partic-
ipant for treatment of soil-transmitted helminths. One participant group received a second
standard single dose of praziquantel (40mg/kg) two weeks after baseline. Before treatments all
participants were offered a snack and a drink in order to minimise adverse events. After treat-
ment participants were observed for two hours for management of possible adverse events. An
experienced nurse directly observed all treatments [24]. After finalisation of the clinical trial in
2007, the whole community including the study participants were treated with a single stan-
dard dose of both praziquantel and albendazole following national guidelines.
Parasitology
Urine samples. Morning to mid-day urine samples [26] for analysis of CCA were col-
lected at six time points; baseline, baseline +24hrs, two weeks, two weeks +24hrs, nine weeks
and two years. Single urine samples were collected from participants and kept cold, swirled
and aliquoted before being frozen at -20˚C for storage until analysis. CCA is a very tempera-
ture stable glycoprotein and read-outs are not affected by multiple freeze-thaw cycles, pro-
longed freezing at only -20˚C or even storage at room temperature for up to weeks (personal
communication G. J. Van Dam). The immunochromatographic carbon-conjugate based CCA
urine strip assay was performed as previously described [27, 28]. This lateral flow urine strip
method is based on CCA-detection by IgG monoclonal antibodies (IgG1 54-4C2-A and IgG3
54-5C10-A [29]) and includes a positive control of polyclonal anti-mouse antibodies, which
catch excess carbon-conjugated antibodies. Briefly, 25ul urine was added to a tube containing
dried carbon conjugated antibody, along with 75uL of buffer and mixed well. Test strips were
Fig 1. Schematical overview of sampling time points and treatment regimens. Diagram showing the
faecal (F) and urine (U) sample collection time points included in this study; baseline (bsl), baseline+24hours
(bsl+24), two weeks (2wks), two weeks+24hours (2wks+24hrs), nine weeks (9wks) and two years (2yrs).
Both praziquantel (PZQ) and albendazole (Alb) was administered to everyone at baseline and the end of the
study (2yrs). An additional dose of PZQ was administered at the two week time point to the two treatments
arm (2 Tx).
https://doi.org/10.1371/journal.pntd.0006054.g001
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added, and allowed to develop for 40 minutes after which the strips were removed. They were
read dry and colour reaction intensity was interpreted by comparison to a dilution standard
series of semi-purified S. mansoni worm antigen containing 3% CCA (0, 10, 100, 1000, 10000
ng/ml). Read-outs100ng/ml were considered positive and assigned a positive score (loga-
rithmic scale) related to increasing colour intensity (score 0,½, 1, 2, 3 respectively). Score 0
was assigned to negative strip readings. A trace measure of 0,5 was given to strip readings of
lower intensity than 100ng/ml. Strips were read by two independent experienced researchers
in a blinded manner. If score discrepancies were found, a third experienced researcher was
consulted to conclude on the score.
Stool samples. Early morning stool specimens were collected on three consecutive days
from all participants. Two slides from each stool specimen were prepared using the modified
Kato-Katz (KK) thick smear method on 50mg templates [30]. The six slides per participant
were examined by experienced technicians using light microscopy at 10x magnification. The
slides were read within one hour for hookworm egg presence and ~24 hours after preparation
for S. mansoni, Ascaris lumbricoides and Trichuris trichiura. 10% of the slides were re-exam-
ined by an independent experienced microscopist for quality control purpose. Variations in S.
mansoni egg counts by quality control were less than 5% (B. J. Vennervald personal communi-
cation). S. mansoni infection intensity was categorised as low (1–99 eggs per gram (EGP)),
moderate (100–399 EPG) and heavy (400 EPG) [31]. Stool investigation was performed at
baseline, after nine weeks and two years as described by Tukahebwa et al. (2013).
Data management and statistical analyses
All data was double-entered in Microsoft Excel 2003 spreadsheet software, where after the data
file was exported to SPSS (IBM) for further analyses. Graphical illustrations were made using
GraphPad Prism 6 software. For all statistical analyses p values of<0.05 were considered signifi-
cant and two tailed tests applied. Hookworm species, A. lumbricoides and T. trichiura results
were only recorded as positive/negative during data collection. Spearman’s correlation co-effi-
cient (rho) was used to describe relationships between CCA score and KK egg intensity. Krus-
kall-Wallis/Mann-Whitney was used to compare mean EPG for 6KK/individual slide EPG and
CCA score stratified by treatment regimen and time points. Mann-Whitney was also used to
investigate associations between CCA and hookworm status. Paired t-tests were applied for
comparing the means of CCA scores with 24 hour intervals. Binary logistic regression models
were used to assess the odds for being CCA positive when positive for S. mansoni (controlled
for hookworm, gender and child/adult) or hookworm eggs.
Results
The total number of recruited participants with CCA and S. mansoni egg count data was 446
individuals, of which 228 (51,1%) were male and 218 (48,9%) female, originating from 243 dif-
ferent households. The median age was 23 years (range 7–76 years). Participants were divided
in two treatment arms stratified by gender and age; 240 individuals received praziquantel only
at baseline while the other arm of 206 individuals received a second dose 2 weeks after baseline.
Demographic, occupational, S. mansoni morbidity and infection intensity (KK) data including
dose related treatment effect were reported in Tukahebwa et al. 2013 and Koukounari et al.
2013 [21, 22]. Prevalence of S. mansoni infection for each sampling time point based on detec-
tion of CCA in urine (trace -/+) or eggs in faeces is shown in Table 1.
In the total sample, the cured proportions determined based on CCA in urine at baseline
(trace considered positive) are 32,3% (104/322; trace = positive) and 41,0% (132/322; trace =
negative) at baseline +24 hours and 36,3% (121/333; trace = positive) and 50,5% (168/333;
Schistosoma mansoni CCA clearance in response to treatment
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trace = negative) at two weeks. For two weeks +24 hours the cured proportions are 50,0%
(67/134; trace = positive) and 66,4% (89/134; trace = negative) in the two treatments arm com-
pared to baseline (trace considered positive). The one treatment group at the two week time
point show cured proportions in response to a single treatment at baseline of 36,4% (43/118;
trace = positive) and 43,2% (51/118; trace = negative). Correspondingly, when considering
trace as negative at baseline, the following cured proportions were observed; baseline +24
hours 30,0% (92/307; trace = positive) and 38,4% (118/307; trace = negative), two weeks 34,9%
(111/318; trace = positive) and 48,7% (155/318; trace = negative), and for the two treatments
arm at two weeks +24 hours 47,2% (60/127; trace = positive) and 64,6% (82/127; trace = nega-
tive). For the one treatment arm the cured proportions are 34,2% (39/114; trace = positive)
and 41,2% (47/114; trace = negative) when assuming trace is negative for baseline measures.
CCA and egg measures (baseline, nine weeks and two years)
CCA score (0,½, 1, 2, 3) and S. mansoni eggs (EPG) were both obtained at baseline, nine
weeks and two years. There was no significant differences between treatment arms for CCA
scores or egg intensities at baseline (CCA p = 0,792, n = 444; eggs p = 0,553, n = 445) or two
years after treatment (CCA p = 0,951, n = 326; eggs p = 0,716, n = 346). However, significantly
lower CCA scores (p = 0,001, n = 399) and fewer eggs (p<0,001, n = 428) were observed at
nine weeks in the two treatments arm compared to the one treatment arm. For S. mansoni egg
positive participants the geometric mean egg count was 253 EPG; 95% CI[212–301] at baseline
(n = 395); 15 EPG, 95% CI[12–19] at nine weeks (n = 170) and 41 EPG; 95% CI[33–52] at two
years (n = 232). S. mansoni prevalence and geometric mean egg counts for each KK slide and
6KK at baseline, 9 weeks and 2 years stratified by treatment regimen can be found in Table A
in S1 Table. The arithmetic mean CCA score for positive participants were 2,2; 95% CI[2,1–
2,3] at baseline (n = 365), 1,3; 95% CI[1,2–1,4] at nine weeks (n = 210) and 1,7; 95% CI[1,6–
1,8] at two years (n = 246) (trace considered positive). CCA data is restricted to a narrow range
of defined assay band intensity related observations (0–3), which limits demonstration of
potential variation and average measures might not be truly representative, but they are used
here in lack of a better method of illustration. Arithmetic mean CCA score and geometric
mean egg counts for the three time points stratified by age groupings and treatment regimens
are shown in Fig 2.
Positive correlations between CCA score and S. mansoni egg intensity were found at
all measured time points (see Table B in S1 Table for CCA score/egg intensity category
Table 1. S. mansoni prevalence (%) measured by urine strip CCA or KK for both treatment arms over time.
Sampling timepoint: Bsl Bsl+24hrs 2 wks 2wks+24hrs 9 wks 2 yrs
CCA Prevalence Tx1 (n)—Tr- 76% (238) 52% (212) 44% (202) 50% (151) 50% (211) 72% (170)
Prevalence Tx1 (n)—Tr+ 80% (238) 63% (212) 54% (202) 56% (151) 60% (211) 76% (170)
Prevalence Tx2 (n)—Tr- 80% (206) 48% (180) 41% (205) 28% (158) 32% (188) 67% (156)
Prevalence Tx2 (n)—Tr+ 84% (206) 56% (180) 58% (205) 44% (158) 44% (188) 74% (156)
1KK Prevalence Tx1 (n) 80% (236) n/a n/a n/a 30% (224) 54% (185)
Prevalence Tx2 (n) 83% (206) n/a n/a n/a 17% (196) 56% (160)
3KK Prevalence Tx1 (n) 89% (239) n/a n/a n/a 48% (228) 67% (186)
Prevalence Tx2 (n) 88% (206) n/a n/a n/a 31% (200) 68% (160)
One KK prevalence is based on data from day 1 KK (Table A in S1 Table: KK slide 1.1 and 1.2). Three KK includes all available KK data from each person
(from 1 to 3 KKs, 1–6 slides). Sample size (n) is given in parentheses. “Tx” = treatment; “Tr-”CCA score 0.5 considered negative; “Tr+” CCA score 0.5
considered positive; “n/a” = not applicable.
https://doi.org/10.1371/journal.pntd.0006054.t001
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distribution data). The correlation was stronger at baseline (p<0,001, n = 443, rho = 0,717)
and after two years (p<0,001, n = 320, rho = 0,691) than at nine weeks (p<0,001, n = 395,
rho = 0,525). Similar findings are obtained when stratifying according to treatment regimen
with better correlation at two years post treatment for both the two treatments arm (p<0,001,
n = 153, rho = 0,762) and one treatment arm (p<0,001, n = 167, rho = 0,611) than at nine
weeks for two treatments (p<0,001, n = 185, rho = 0,430) and one treatment (p<0,001,
n = 210, rho = 0,554).
Soil transmitted helminths (baseline, nine weeks and two years)
The prevalence of A. lumbricoides was very low. Only one individual was found infected at
baseline (n = 430), none at 9 weeks (n = 426) and at two years a different single egg positive
individual was found (n = 341). No individuals were at any time point found to be T. trichiura
egg positive. The hookworm species prevalence was 44,3% (193 of 436) at baseline, 5,6% (24 of
425) at nine weeks and 28,0% (97 of 346) at two years. Of the individuals with hookworm data
Fig 2. S. mansoni egg counts and CCA scores stratified by age groups and treatment arms. a) and b) Boxplot with whiskers (5-95th
percentile) showing S. mansoni EPG (mean of all obtained KK/individual) related to participant age for a) the one treatment arm (nbsl = 239, n9wks =
228, n2yrs = 186) and b) the two treatments group (nbsl = 206, n9wks = 200, n2yrs = 160) at three time points. Circles depict outliers. Medians are
indicated with horizontal bars and the means with small “+”. The top and bottom of the box represent the 75th and 25th percentile respectively. c)
and d) show mean CCA score ±95% CI stratified by age groups for c) the one treatment arm (nbsl = 238, n9wks = 211, n2yrs = 170) and d) the two
treatments arm (nbsl = 206, n9wks = 188, n2yrs = 156) at three time points. The distribution for all samples per time point is shown at the far right on
all subfigures.
https://doi.org/10.1371/journal.pntd.0006054.g002
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both at baseline and nine weeks, 180 were positive at baseline of which 20 remained positive at
nine weeks. Of these thirteen individuals remained hookworm infected at two years post treat-
ment (76,5%, n = 17).
Among S. mansoni egg negative individuals there was no association between hookworm
and being CCA positive at baseline (p = 0,569, n = 48), nine weeks (p = 0,990, n = 235) or two
years (p = 0,348, n = 104) post treatment. In binary univariate logistic regression models the
following odds ratios were obtained for being CCA positive when hookworm egg positive at
baseline (n = 48, OR = 1,5; 95% CI[0,4–5,5] (trace = positive)/OR = 1,9; 95% CI[0,4–8,7]
(trace = negative)), nine weeks(n = 235, OR = 1,1; 95% CI[0,3–4,6] (trace = positive)/OR = 0,5;
95% CI[0,06–3,8] (trace = negative)), and two years (n = 104, OR = 0,7; 95% CI[0,3–1,5]
(trace = positive)/OR = 0,8; 95% CI[0,3–1,8] (trace = negative)) for the S. mansoni egg negative
(6KK) subgroups.
Short term CCA score dynamics
Twenty four hours after baseline 74,9% of CCA positives (n = 339) have a decline of1 score
unit after treatment (Table 2, Table C in S1 Table), whereas only 3,5% have an increase of1
score unit. 12,4% had unchanged positive CCA scores. With respect to trace scores 5,3% and
3,2% showed a decline or increase of1 score unit, respectively, whereas only 0,6% remained
unchanged as trace positives. Fifteen individuals had trace positive score at baseline whereof
80% (12) were negative 24 hours later, two remained as trace positive and only one observation
showed an increase in score to “1” (Table C in S1 Table). The mean CCA scores at baseline
and 24 hours after treatment were significantly different (p<0.001). Mean CCA score [±95%
CI] stratified by age groups for baseline and plus 24 hours is shown in Fig 3A.
The extend of daily fluctuations in measured CCA levels can be observed at two weeks
where 18,8% (n = 101) of CCA positives only treated at baseline (1 Tx) had a decline in CCA
score of1 at plus 24 hours and 26,7% had an increase of1 (Table 2, Table C in S1 Table);
35,6% had an unchanged positive score in this group. Comparably, 34,3% had a decline and
only 7% had an increase in CCA score of1 at 24 hours post treatment in the arm being
treated at two weeks (2 Tx). In the two treatments arm 28,3% had an unchanged positive
score. However, the arm only having received treatment at baseline (n = 147) show no signifi-
cant difference in means at two weeks and two weeks plus 24 hours (p = 0,568). In contrast,
Table 2. Change in CCA score units in response to treatment 24 hours after baseline and two weeks.
Change in CCA score Bsl -> bsl + 24hrs 2 wks-> 2wks + 24hrs
n 1 Tx, n 2 Tx, n
 1 # 254 19 34
 1 " 12 27 7
0,5 # 18 13 21
0,5 " 11 6 9
1/2/3! 1/2/3 42 35 20
0,5! 0,5 2 1 8
0! 0 53 46 58
Total 392 147 157
Horizontal arrow indicates no change in score, upwards arrows indicate a rise in score and downwards
arrows a decrease in score. Only individuals, who gave a urine sample at a time point (bsl and/or 2wks) and
another sample at +24hrs, are included. Non-summarised score changes can be seen in Table C in S1
Table.
https://doi.org/10.1371/journal.pntd.0006054.t002
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the arm receiving a second treatment at two weeks (n = 157) has a significantly lower mean
CCA score 24 hours post-treatment (p<0,001). At the two week time point 25 individuals
scored trace positive in the two treatments arm and 13 responded to treatment and scored
Fig 3. Short term CCA scores in response to treatment. The mean CCA scores with 95% confidence
intervals stratified by age groupings are shown for a) baseline and baseline+24hours (ntotal = 392) and b) two
weeks and two weeks + 24hours further stratified by treatment regimen (n1Tx = 147, n2Tx = 157). Only
individuals, who gave a urine sample at a time point (bsl and/or 2wks) and another sample at +24hrs, are
included. “Trace” is included as score 0,5.
https://doi.org/10.1371/journal.pntd.0006054.g003
Table 3. Comparison of CCA scores at +24hrs after baseline treatment vs. two weeks.
CCA score 2 wks (n) Total (n)
0 0.5 1 2 3
Bsl+24hrs
1Tx
n = 359
0 102 13 25 5 0 145
0,5 13 + 2 5 14 2 0 36
1 25 14 + 3 24 19 3 88
2 5 + 13 2 + 6 19 + 7 17 4 + 2 75
3 2 0 3 + 1 4 5 15
Total 162 43 93 47 14 359
Light grey fill indicates an unchanged score from baseline (bsl) +24hours to two weeks (wks). Bold shown as “+ n” indicates the number for discrepant
score values from baseline +24hours to two weeks on an overall sample level; for example, there are 18 observations of a score going from 2 to 0 but only 5
going from 0 to 2, meaning there is a discrepancy of + 13 in this score change category.
https://doi.org/10.1371/journal.pntd.0006054.t003
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negative 24 hours later (Table C in S1 Table). Eight remained trace positive and only four
showed an increase in score. In comparison seven individuals from the one treatment arm
showed trace positive scores at two weeks and a negative score at two weeks +24 hours. Only
one individual remained trace positive and 5 had an increased score at two weeks + 24hours.
Mean CCA score [±95%CI] stratified by age groups for two weeks and two weeks plus 24
hours is shown in Fig 3B.
CCA scores at the baseline +24 hours and two week time points both reflect measurements
of antigen in urine after a single treatment at baseline only. Table 3 shows the number of indi-
viduals (n) with a given score at baseline+24hrs after treatment and the corresponding score at
two weeks post-treatment. Forty-three percent (n = 359) of individuals had an unchanged
score from baseline +24hours to the two week time point. When considering change in score
at sample level, only 36 discrepancies are observed (Table 3). Out of these score differences 19
are positive at both time points with a trend of lower score at two weeks, leaving only 17 (5%)
observations positive at baseline +24hrs after treatment, which are negative at two weeks, giv-
ing an overestimation of prevalence compared to two weeks post-treatment (60% vs 55%, trace
considered positive).
Discussion
Short timeframe CCA measures in response to treatment
In order to design the best possible interventions aiming at breaking S. mansoni transmission,
availability of accurate diagnostic tools detecting live worms and thus active infection is cru-
cial. Such tools can improve the understanding of the actual efficacy of treatment and propor-
tion of re-infection both of which are currently based on faecal egg counts (KK). When
evaluation of treatment efficacy is based on classical faecal egg counts alone, a portrayal of
poor treatment efficacy may be the result as eggs produced by newly matured worms and eggs
lodged in tissue and being released over a period of time, despite clearance of worms, will pres-
ent as treatment failure. For antigen-based diagnostic tools, it is necessary to know whether
the detected antigen is removed from circulation in response to treatment, as it is otherwise
impossible to interpret whether this tool can be used to evaluate re-infection levels and treat-
ment efficacy. To our knowledge this is the first report describing a consistently detectable
decline of CCA after only 24 hours in response to praziquantel treatment in a community
based study using the urine strip test. The decreased level of CCA in response to this first
round of mass drug administration in this community could be observed both after baseline
treatment and again at two weeks in the two treatments arm, albeit to a lesser extent quite pos-
sibly due to the already lowered worm burden. This supports the hypothesis that positive CCA
measures 24 hours after treatment reflect the presence of CCA derived from immature worms,
which are not susceptible to praziquantel [8], as well as from adult worms surviving PZQ treat-
ment. A proportion of these immature worms will then have matured by the two week time
point and treatment will take effect at the second administration. Murine experimental work
support this view as studies have shown that CCA is detectable in liver tissue as early as two
weeks post infection depending on infection dose [16, 32]. Our own observations (personal
communication A. Kildemoes) show detectable CCA in mouse urine based on the POC-CCA
test from 2,5 weeks post-infection depending on infection intensity. These observations point
towards CCA being excreted as soon as the immature worms start feeding in the bloodstream.
Our observations of consistently declining CCA short term levels in response to praziquantel
treatment in the vast majority of this community sample indicate that CCA measures can bear
more weight in terms of interpreting treatment efficacy, potential resistance and re-infection
patterns. Repeated CCA measures in individuals could potentially be used to assess how
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susceptible adult worms are to praziquantel and provide information on potential up-concen-
tration of less susceptible worm populations. The consistent decline in CCA measures was
observed despite the fact that differences in clearance rate in response to treatment are to be
expected due to varying initial infection intensity, daily CCA level fluctuations and host
metabolism. For individual diagnosis this tool should ideally be used in combination with
other diagnostic measures such as egg counts or schistosomal DNA in faecal matter in order to
gain a clearer picture of the true burden of infection and related disease manifestations in the
host.
Interpretation of trace positive results; sensitivity and specificity
Both the lateral flow test used here and the POC-CCA test have showed good specificity and
sensitivity for S. mansoni in large studies including sub-Saharan multi-country settings [33,
34], however the interpretation of trace measures need elucidation. More stable performance
by CCA than KK on this study’s data is shown by estimated sensitivities and specificities for
both diagnostic methods fitted in a latent markov model with no gold standard assumed and
published in Koukounari et al. (2013) [21]. Traditionally calculated comparisons of CCA to
KK performance can be found in Table A in S1 Supporting information. Lamberton et al.
(2014) argues that trace measures should be considered positive based on a study carried out
in children from an endemic area in Uganda comparing a 6KK as standard with a single urine
sample tested with POC-CCA [35]. The data presented here support this view as we observe a
response to treatment in the majority of trace positives within 24hrs at both treatment time
points (Table C in S1 Table).
The strip test used for this study has a comparable sensitivity to the POC-CCA, hence the
current results point towards trace measures in POC-CCA to be considered as positives in
populations comparable to the sample studied here. This is particularly relevant in high preva-
lence areas in a mass drug administration context as the additional drug cost and minimal pra-
ziquantel adverse effects can be perceived as acceptable even if a small proportion of trace
positives are indeed S. mansoni negative. However, more knowledge on sensitivity and speci-
ficity in terms of potential false positives due to cross-reactivity mediated by other helminth
infections is needed, when operating in low-endemic settings and/or when elimination is tar-
geted and a test-then-treat approach is implemented. When testing cross-reactivity on sera
and urine from people infected with parasites it is important to take both biological compart-
mentalisation and geographical epidemiology into account. Worms with stages feeding within
the human host would logically heighten the possibility of presence of regurgitated antigens.
Some of these could potentially share epitopes with CCA. Furthermore, killing of tissue dwell-
ing or migratory stages could release antigens to the same host tissue compartments as schisto-
somes. This could be the case with migratory or tissue dwelling stages of parasites such as
filarial nematodes, Fasciola spp. or in cysticercosis. The monoclonal IgG antibody, which rec-
ognise CCA from adult and immature actively feeding schistosomes and not egg-derived CCA
[29, 36, 37], used in this study and in the POC-CCA, has been tested for cross-reactivity on
sera from people infected with a range of parasites [15, 38]. However, the sample sizes for each
parasite is very small and further studies are needed to identify to which extent false-positives
occur. Here we showed that the often co-endemic hookworm infection is not likely to be a
confounder for the assay as there is no association observed between hookworm and CCA pos-
itivity (irrespective of traces being interpreted as positive or negative). Recently, caution in
terms of interpreting test read-outs of the POC-CCA when used in pregnant women has been
raised [39]. Pregnant women may present with a changed Lewis-X moiety level in urine and
this could possibly increase the background. However, while more research is needed in order
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to elucidate potential cross reactions, current data support the application of the available
CCA tests into the existing schistosomiasis epidemiology and diagnostics toolbox [40, 41].
Application of the tests should be combined with guidelines for use and interpretation of test
results, which are suited for mass drug administration based control programmes and indi-
vidual diagnosis in test-then treat approaches, respectively. Both the current study based on
urine strip CCA test in a community sample and POC-CCA studies in children even in a low
endemic sub-Saharan settings have presented less variability and better or comparable sensitiv-
ity of CCA than a single KK alone [21, 42–44], despite the fact that daily CCA fluctuations
exist [42].Furthermore, application in combination with other tools in a migrant and traveller
context with histories of exposure to fresh water in S. mansoni endemic regions is also relevant
as it opens up for earlier detection of infection and better clinical management [45]. Potential
discrepancies in interpretation of colour reaction development is particularly relevant in the
context of trace/no trace scoring in terms of inter-reader variability [26].
Expanded applicability of CCA measures
For monitoring treatment efficacy purposes, it is relevant to compare the prevalence outcomes
obtained at baseline+24hrs and the two weeks after treatment time points. An overall pre-
valence deemed similar at these two time points equals a logistical advantage for screening
strategies. 43% of individuals, who gave urine samples at both time points (n = 359), had an
unchanged score (Table 3). Only 10% of observations differ at overall sample level at the two
time points in terms of intensity of infection. The majority of these discrepant scores are posi-
tive at both time points, which doesn’t affect prevalence estimations at population level. The
remaining observations with a positive score at baseline+24 hours and score 0 at the two week
time point constitute only 5% resulting in a marginal overestimation of prevalence. The find-
ing that a prevalence estimate made 24hrs after baseline treatment based on a single urine strip
CCA test presented only a small over-estimation of prevalence compared to the two week
time-point as result of a single treatment, provide prospects of using this tool as a cost-effective
prevalence screening method [46]. A team could gain the same information on a single over-
night field site visit compared to deploying a team a second time. There might also be positive
compliance outcomes of such a strategy as people are already on site combined with the more
socially acceptable and ease of delivery urine sample compared with faecal sampling. Further-
more, this would provide basis for administration of a second dose of praziquantel to individu-
als with residual high scores to maximize the efficacy of treatment either immediately and/or
administered two to three weeks later by a community worker in order to allow immature
worms to mature and become drug susceptible.
Concluding remarks
A consistently measurable decline in CCA levels is seen in urine already 24 hours after both a
single and a second praziquantel treatment in a community sample. The decline in CCA in
response to treatment occurs in the majority of individuals even for trace measurements,
which supports that trace should be considered positive in populations and transmission
zones comparable to this study. These observations inform use of and provide weight to fur-
ther interpretation of CCA based diagnostics and support extended applicability of the CCA
based tools for S. mansoni in control programmes and on individual diagnostics level.
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